Foam: A Unique Delivery Vehicle for Topically Applied Formulations

Tamarkin, Dov

doi:10.1002/9781119364221.ch9

Cited by 18 publications

(18 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 The foam is unique because it allows minocycline to exist as a suspended, micronized active ingredient, improving skin penetration 7 and avoiding a grainy sensation on the skin. 8 The main excipients (soybean oil, coconut oil, light mineral oil, and cyclomethicone 5) were chosen for their compatibility with minocycline and their association with moisturizing effects. [9][10][11] Pharmacokinetic studies have evaluated the extent of systemic exposure with use of the minocycline foam formulation.…”

mentioning

confidence: 99%

Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials

Gold

Rosso²,

Kircik

et al. 2020

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Background: Efficacious topical medications for rosacea are needed. FMX103 1.5% is a novel topical minocycline foam that may have therapeutic benefits in treating rosacea while minimizing systemic adverse effects due to its topical route of delivery. Objective: To determine the efficacy, safety, and tolerability of 12 weeks of treatment with FMX103 1.5% topical minocycline foam for papulopustular rosacea. Methods: Two 12-week, phase 3, randomized, multicenter, double-blind, vehicle-controlled, 2-arm studies were performed in patients with moderate to severe papulopustular rosacea. Results: Participants who received FMX103 1.5%, versus control individuals treated with vehicle, exhibited a significantly greater reduction in the number of inflammatory lesions (FX2016-11:-17.57 vs-15.65; P = .0031; FX2016-12:-18.54 vs-14.88; P \ .0001) and higher rates of Investigator Global Assessment treatment success (FX2016-11: 52.1% vs 43.0%; P = .0273; FX2016-12: 49.1% vs 39.0%; P = .0077). No serious treatment-related treatment-emergent adverse events occurred. Limitations: The generalizability of these data from a controlled clinical trial should be examined in a real-world setting. Conclusions: FMX103 1.5% was efficacious for moderate to severe papulopustular rosacea and maintained a favorable safety profile.

show abstract

mentioning

confidence: 99%

Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials

Gold

Rosso²,

Kircik

et al. 2020

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

show abstract

“…Foams can be classified in several ways. We can differentiate aqueous, hydroethanolic and emollient foams as well as petrolatum-, oil-or other solvent-based foams too [13].…”

Section: Classification Of Foamsmentioning

confidence: 99%

“…Water-free foams that enable water-insoluble or unstable active ingredients to be used in the form of foams are also under development. The formulation would prevent microorganism growth, making preservatives unnecessary and could maximize the emollient effect [13].…”

Section: Classification Of Foamsmentioning

confidence: 99%

See 1 more Smart Citation

Foams as carrier systems for pharmaceuticals and cosmetics

Farkas

Kállai-Szabó

Antal

2019

APH

View full text Add to dashboard Cite

Foams are becoming more and popular in several areas of our lives, including pharmaceutics and cosmetics. They are colloid systems where gas is dispersed in liquid phase Active ingredient bearing pharmaceutical foams are traditionally applied topically (dermal, local rectal, vaginal), but formulations for other delivery routes (e.g. nanosystems parenterally, solid foams orally) are also available. Numerous advantages are attached to foams when compared to traditional vehicles, resulting in increased patient compliance. Amongst others, the suitable composition contributes to quick, oily residue‑free and convenient application even on large or hairy areas, as well as to good drug transfer rate.

show abstract

“…By definition, “chemically stable” is showing substantially none or minimal breakdown from oxidation in 3 days after mixing with the agent or the carrier while kept at 25°C minimum. According to recent patents and studies, foamable compositions have exhibited usefulness in this regard [73, 74]. Various recent patents can be found in Table 4 and structures in (Figs.…”

Section: Topical Antibioticsmentioning

confidence: 99%

Topical Antimicrobials for Burn Infections – An Update

Sevgi¹,

Toklu²,

Vecchio³

et al. 2014

PRI

View full text Add to dashboard Cite

The relentless rise in antibiotic resistance among pathogenic bacteria and fungi, coupled with the high susceptibility of burn wounds to infection, and the difficulty of systemically administered antibiotics to reach damaged tissue, taken together have made the development of novel topical antimicrobials for burn infections a fertile area of innovation for researchers and companies. We previously covered the existing patent literature in this area in 2010, but the notable progress made since then, has highlighted the need for an update to bring the reader up to date on recent developments. New patents in the areas of topically applied antibiotics and agents that can potentiate the action of existing antibiotics may extend their useful lifetime. Developments have also been made in biofilm-disrupting agents. Antimicrobial peptides are nature’s way for many life forms to defend themselves against attack by pathogens. Silver has long been known to be a highly active antimicrobial but new inorganic metal derivatives based on bismuth, copper and gallium have emerged. Halogens such as chlorine and iodine can be delivered by novel technologies. A variety of topically applied antimicrobials include chitosan preparations, usnic acid, ceragenins and XF porphyrins. Natural product derived antimicrobials such as tannins and essential oils have also been studied. Novel techniques to deliver reactive oxygen species and nitric oxide in situ have been developed. Light-mediated techniques include photodynamic therapy, ultraviolet irradiation, blue light, low-level laser therapy and titania photocatalysis. Passive immunotherapy employs antibodies against pathogens and their virulence factors. Finally an interesting new area uses therapeutic microorganisms such as phages, probiotic bacteria and protozoa to combat infections.

show abstract

Foam: A Unique Delivery Vehicle for Topically Applied Formulations

Cited by 18 publications

References 8 publications

Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials

Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials

Foams as carrier systems for pharmaceuticals and cosmetics

Topical Antimicrobials for Burn Infections – An Update

Contact Info

Product

Resources

About